Vancomycin-resistente Enterokokken: Erhöhte Sterblichkeit durch Tigecyclin?

Nico T. Mutters; Alexander Mischnik

doi:10.1055/s-0041-102303

DMW - Deutsche Medizinische Wochenschrift, Inhaltsverzeichnis

Dtsch Med Wochenschr 2015; 140(11): 784
DOI: 10.1055/s-0041-102303

Erwiderung

Vancomycin-resistente Enterokokken: Erhöhte Sterblichkeit durch Tigecyclin?

Vancomycin-resistant enterococci: increased mortality with tigecycline?

Nico T. Mutters

¹Deutsches Zentrum für Infektionsforschung (DZIF) Heidelberg, Universitätsklinikum Heidelberg

²Department für Infektiologie, Medizinische Mikrobiologie und Hygiene, Universitätsklinikum Heidelberg

,

Alexander Mischnik

¹Deutsches Zentrum für Infektionsforschung (DZIF) Heidelberg, Universitätsklinikum Heidelberg

²Department für Infektiologie, Medizinische Mikrobiologie und Hygiene, Universitätsklinikum Heidelberg

Literatur
1 Cai Y, Wang R, Liang B et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011; 55: 1162-1172
2 FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. 2013. http://wwwfdagov/Drugs/DrugSafety/ucm369580htm
3 FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. 2010. http://wwwfdagov/Drugs/DrugSafety/ucm224370htm
4 Freire AT, Melnyk V, Kim MJ et al. Comparison of tigecycline with imipenem / cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68: 140-151
5 Mischnik A, Kaase M, Lubbert C et al. [Carbapenem-resistance in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii]. Dtsch Med Wochenschr 2015; 140: 172-176
6 Ramirez J, Dartois N, Gandjini H et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013; 57: 1756-1762
7 Tasina E, Haidich AB, Kokkali S et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011; 11: 834-844
8 Yahav D, Lador A, Paul M et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66: 1963-1971